Heather P. Whitley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heather P. Whitley has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Jason M. Parton
Culverhouse College of Business Institute of Business Analytics, The University of Alabama, Tuscaloosa, USA
4 shared publicationsCourtney Hanson
Culverhouse College of Business Institute of Business Analytics, The University of Alabama, Tuscaloosa, USA
3 shared publications- Surachat Ngorsuraches
Harrison College of Pharmacy, Auburn University, Auburn, USA
2 shared publications Warren D. Smith
Department of Drug Discovery and Development, Auburn University Harrison School of Pharmacy, Auburn, USA
2 shared publications- Warren D. Smith
Doctor of Philosophy Student, Department of Drug Discovery and Development, Auburn University Harrison College of Pharmacy; Auburn, Alabama, USA
2 shared publications Anna Albritton
Camp Kudzu Atlanta GA USA
1 shared publication
Latest Publications
- 28 August 2025
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 43 (5) , 670-680
Important Continuous Glucose Monitoring Attributes for Patients With Type 2 Diabetes
Although patient preferences are heterogeneous, the out-of-pocket cost and accuracy of continuous glucose monitoring (CGM) systems are the two most important attributes for patients with type 2 diabetes. Surprisingly, receiver screen information is not considered important when choosing a CGM system. Identifying important attributes could facilitate patient-provider communications in choosing a preferred CGM system and potentially increase adherence. Improving patient education on interpreting the information on the receiver screen could enhance the benefit of using CGM.
- 28 August 2025
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 43 (5) , 670-680
Important Continuous Glucose Monitoring Attributes for Patients With Type 2 Diabetes
Although patient preferences are heterogeneous, the out-of-pocket cost and accuracy of continuous glucose monitoring (CGM) systems are the two most important attributes for patients with type 2 diabetes. Surprisingly, receiver screen information is not considered important when choosing a CGM system. Identifying important attributes could facilitate patient-provider communications in choosing a preferred CGM system and potentially increase adherence. Improving patient education on interpreting the information on the receiver screen could enhance the benefit of using CGM.
- 28 February 2025
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 43 (3) , 439-441
Triple Agonist Therapy: A New Frontier in Treating Type 2 Diabetes and Obesity
- 28 February 2025
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 43 (3) , 439-441
Triple Agonist Therapy: A New Frontier in Treating Type 2 Diabetes and Obesity
- 28 February 2025
- Published by Wiley in Medical Education
- Vol. 59 (7) , 765-766
Teaching diabetes‐specific patient‐centered care using fictional pop‐culture characters
- 28 February 2025
- Published by Wiley in Medical Education
- Vol. 59 (7) , 765-766
Teaching diabetes‐specific patient‐centered care using fictional pop‐culture characters
- Open Access
- 29 April 2023
- Published by Edorium Journals Pvt. Ltd. in Journal of Case Reports and Images in Medicine
- Vol. 9 (1) , 4-10
Adjusting background insulin therapy in type 2 diabetes when initiating a glucagon-like peptide 1 receptor agonist: A case series
Introduction: Guidelines recommend preferential use of antihyperglycemic medications with proven cardiovascular benefit for the treatment of patients with type 2 diabetes with established atherosclerotic cardiovascular disease (ASCVD), high risk factors for ASCVD, kidney disease, or heart failure. However, current guidelines offer little to no practical recommendations for adding these therapies to a patient’s current regimen while avoiding hyperglycemia or hypoglycemia. Nevertheless, considering background therapy in a proactive effort to avoid undesirable glycemic excursions when initiating any new antidiabetic medication remains paramount. Case Series: A six-patient case series investigates adjustments to background therapies and glycemic outcomes surrounding the initiation and titration of long-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to shed light on practical methods to manage patient care during this tenuous phase. Overarching findings regarding background therapy adjustments to avoid hypoglycemia when initiating a GLP-1 RA include: (1) safe continuation of metformin regardless of baseline A1C or concurrent glycemic background therapy; (2) continuation of background therapy when the baseline A1C is above 9%; (3) consideration of a proactive 15–20% basal insulin dose reduction when the baseline A1C is below 7.5%; (4) proactive bolus insulin dose reduction by 25% or complete discontinuation at the time of GLP-1 RA initiation. Conclusion: No dose adjustments are necessary when A1C > 9%, and possibly >8%. When A1C is <7.5% and possibly <8%, discontinue or reduce bolus insulin by 25% and/or reduce basal insulin by 15–25%. Adjust background therapy using shared-decision making while considering fasting blood glucose, A1C, hypoglycemia risk, and chosen GLP-1 RA therapy.
- 29 April 2023
- Published by Edorium Journals Pvt. Ltd. in Journal of Case Reports and Images in Medicine
- Vol. 9 (1) , 4-10
Open AccessAdjusting background insulin therapy in type 2 diabetes when initiating a glucagon-like peptide 1 receptor agonist: A case series
Introduction: Guidelines recommend preferential use of antihyperglycemic medications with proven cardiovascular benefit for the treatment of patients with type 2 diabetes with established atherosclerotic cardiovascular disease (ASCVD), high risk factors for ASCVD, kidney disease, or heart failure. However, current guidelines offer little to no practical recommendations for adding these therapies to a patient’s current regimen while avoiding hyperglycemia or hypoglycemia. Nevertheless, considering background therapy in a proactive effort to avoid undesirable glycemic excursions when initiating any new antidiabetic medication remains paramount. Case Series: A six-patient case series investigates adjustments to background therapies and glycemic outcomes surrounding the initiation and titration of long-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to shed light on practical methods to manage patient care during this tenuous phase. Overarching findings regarding background therapy adjustments to avoid hypoglycemia when initiating a GLP-1 RA include: (1) safe continuation of metformin regardless of baseline A1C or concurrent glycemic background therapy; (2) continuation of background therapy when the baseline A1C is above 9%; (3) consideration of a proactive 15–20% basal insulin dose reduction when the baseline A1C is below 7.5%; (4) proactive bolus insulin dose reduction by 25% or complete discontinuation at the time of GLP-1 RA initiation. Conclusion: No dose adjustments are necessary when A1C > 9%, and possibly >8%. When A1C is <7.5% and possibly <8%, discontinue or reduce bolus insulin by 25% and/or reduce basal insulin by 15–25%. Adjust background therapy using shared-decision making while considering fasting blood glucose, A1C, hypoglycemia risk, and chosen GLP-1 RA therapy.
- Open Access
- 29 April 2023
- Published by Edorium Journals Pvt. Ltd. in Journal of Case Reports and Images in Medicine
- Vol. 9 (1) , 4-10
Adjusting background insulin therapy in type 2 diabetes when initiating a glucagon-like peptide 1 receptor agonist: A case series
Introduction: Guidelines recommend preferential use of antihyperglycemic medications with proven cardiovascular benefit for the treatment of patients with type 2 diabetes with established atherosclerotic cardiovascular disease (ASCVD), high risk factors for ASCVD, kidney disease, or heart failure. However, current guidelines offer little to no practical recommendations for adding these therapies to a patient’s current regimen while avoiding hyperglycemia or hypoglycemia. Nevertheless, considering background therapy in a proactive effort to avoid undesirable glycemic excursions when initiating any new antidiabetic medication remains paramount. Case Series: A six-patient case series investigates adjustments to background therapies and glycemic outcomes surrounding the initiation and titration of long-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to shed light on practical methods to manage patient care during this tenuous phase. Overarching findings regarding background therapy adjustments to avoid hypoglycemia when initiating a GLP-1 RA include: (1) safe continuation of metformin regardless of baseline A1C or concurrent glycemic background therapy; (2) continuation of background therapy when the baseline A1C is above 9%; (3) consideration of a proactive 15–20% basal insulin dose reduction when the baseline A1C is below 7.5%; (4) proactive bolus insulin dose reduction by 25% or complete discontinuation at the time of GLP-1 RA initiation. Conclusion: No dose adjustments are necessary when A1C > 9%, and possibly >8%. When A1C is <7.5% and possibly <8%, discontinue or reduce bolus insulin by 25% and/or reduce basal insulin by 15–25%. Adjust background therapy using shared-decision making while considering fasting blood glucose, A1C, hypoglycemia risk, and chosen GLP-1 RA therapy.
- 29 April 2023
- Published by Edorium Journals Pvt. Ltd. in Journal of Case Reports and Images in Medicine
- Vol. 9 (1) , 4-10
Open AccessAdjusting background insulin therapy in type 2 diabetes when initiating a glucagon-like peptide 1 receptor agonist: A case series
Introduction: Guidelines recommend preferential use of antihyperglycemic medications with proven cardiovascular benefit for the treatment of patients with type 2 diabetes with established atherosclerotic cardiovascular disease (ASCVD), high risk factors for ASCVD, kidney disease, or heart failure. However, current guidelines offer little to no practical recommendations for adding these therapies to a patient’s current regimen while avoiding hyperglycemia or hypoglycemia. Nevertheless, considering background therapy in a proactive effort to avoid undesirable glycemic excursions when initiating any new antidiabetic medication remains paramount. Case Series: A six-patient case series investigates adjustments to background therapies and glycemic outcomes surrounding the initiation and titration of long-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs) to shed light on practical methods to manage patient care during this tenuous phase. Overarching findings regarding background therapy adjustments to avoid hypoglycemia when initiating a GLP-1 RA include: (1) safe continuation of metformin regardless of baseline A1C or concurrent glycemic background therapy; (2) continuation of background therapy when the baseline A1C is above 9%; (3) consideration of a proactive 15–20% basal insulin dose reduction when the baseline A1C is below 7.5%; (4) proactive bolus insulin dose reduction by 25% or complete discontinuation at the time of GLP-1 RA initiation. Conclusion: No dose adjustments are necessary when A1C > 9%, and possibly >8%. When A1C is <7.5% and possibly <8%, discontinue or reduce bolus insulin by 25% and/or reduce basal insulin by 15–25%. Adjust background therapy using shared-decision making while considering fasting blood glucose, A1C, hypoglycemia risk, and chosen GLP-1 RA therapy.
- 24 April 2023
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 15 (4) , 360-367
National survey of educational impact on pharmacy learners by volunteering at camps for children with diabetes
- 24 April 2023
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 15 (4) , 360-367
National survey of educational impact on pharmacy learners by volunteering at camps for children with diabetes
- Top Cited PapersOpen Access
- 7 April 2023
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 41 (3) , 467-473
Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent
- 7 April 2023
- Published by American Diabetes Association in Clinical Diabetes
- Vol. 41 (3) , 467-473
Top Cited PapersOpen AccessSpecial Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
Unexpected drug shortages of the long-acting glucagon-like peptide 1 (GLP-1) receptor agonists dulaglutide and semaglutide and the dual GLP-1/glucose-dependent
- Open Access
- 1 December 2022
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 16, 3415-3428
Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Purpose: To determine patients’ preferences for sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs). Patients and Methods: A cross-sectional, web-based discrete choice experiment was conducted among US adults with type 2 diabetes mellitus (T2DM) in May 2021. Six attributes—the route and frequency of administration, the chance of reaching target HbA1c in six months, the percentage reduction in the risk of major adverse cardiovascular events (MACE), the chance of gastrointestinal side effects, the chance of genital infection, and out-of-pocket cost per month—were identified from literature review and consultation with patients and clinicians. A Bayesian efficient design was used to generate choice sets. Each choice set contained two hypothetical SGLT-2i and GLP-1 RA alternatives described by the attributes and an opt-out alternative. A total of 176 patients were asked to select the most preferred option from each choice set. Mixed logit (ML) and latent class (LC) models were developed. The conditional relative importance of each attribute was determined. Results: The ML model showed the out-of-pocket cost had the highest conditional relative importance, followed by the chance of reaching the target HbA1c. The best LC model revealed two patient classes. All attributes were significantly important to the patients in both classes, except the chance of genital infection in class 2. Compared to the patients in class 2, the patients in class 1 were older (approximately 65 vs 56 years) and had a higher number of comorbidities (approximately three vs two). Conclusion: T2DM patients placed different preference weights or importance across SGLT-2i and GLP-1 RA attributes. Preference heterogeneity was found among patients with different ages and numbers of comorbidities.
- 1 December 2022
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 16, 3415-3428
Open AccessPatients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Purpose: To determine patients’ preferences for sodium-glucose cotransporter 2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs). Patients and Methods: A cross-sectional, web-based discrete choice experiment was conducted among US adults with type 2 diabetes mellitus (T2DM) in May 2021. Six attributes—the route and frequency of administration, the chance of reaching target HbA1c in six months, the percentage reduction in the risk of major adverse cardiovascular events (MACE), the chance of gastrointestinal side effects, the chance of genital infection, and out-of-pocket cost per month—were identified from literature review and consultation with patients and clinicians. A Bayesian efficient design was used to generate choice sets. Each choice set contained two hypothetical SGLT-2i and GLP-1 RA alternatives described by the attributes and an opt-out alternative. A total of 176 patients were asked to select the most preferred option from each choice set. Mixed logit (ML) and latent class (LC) models were developed. The conditional relative importance of each attribute was determined. Results: The ML model showed the out-of-pocket cost had the highest conditional relative importance, followed by the chance of reaching the target HbA1c. The best LC model revealed two patient classes. All attributes were significantly important to the patients in both classes, except the chance of genital infection in class 2. Compared to the patients in class 2, the patients in class 1 were older (approximately 65 vs 56 years) and had a higher number of comorbidities (approximately three vs two). Conclusion: T2DM patients placed different preference weights or importance across SGLT-2i and GLP-1 RA attributes. Preference heterogeneity was found among patients with different ages and numbers of comorbidities.
- 9 January 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (2) , 177-187
Systematic literature review of insulin dose adjustments when initiating hemodialysis or peritoneal dialysis
Chronically uncontrolled hyperglycemia is the leading cause of end stage kidney disease (ESKD) necessitating dialysis. During times of transition to hemodialysis (HD) or peritoneal dialysis (PD), considerations must be given to insulin dosing adjustments for persons with diabetes (PWD) in efforts to maintain glycemic control. However, the literature is sparse with few clear and direct practical clinical recommendations for therapeutic insulin dosing adjustments in PWD and ESKD. The objective of this systematic review was to identify and report the evidence and gaps in the literature for adjustments in therapeutic insulin recommendations when initiating HD or PD in patients with ESKD and diabetes mellitus. A literature search using PubMed, CENTRAL, MEDLINE, CINAHL, Google Scholar, and ClinicalTrials.gov revealed 242 results. After removing duplicates and articles not reaching pre‐specified criteria, 29 relevant articles remained for further analysis. Following the exclusion of 18 articles after full‐text review due to lack of relevance or inappropriate publication type, 11 articles remained and were included in the review. The most common recommendation regarding HD was to reduce the basal insulin dose up to 25% on HD days to prevent hypoglycemia, although a lack of consensus exists on the percent reduction. Little information was found relating to insulin management with continuous ambulatory PD or automated PD. During PD, insulin may be administered subcutaneously, IP, or with the dialysis fluid. Administration of insulin with dialysate may necessitate a dose increase of up to 30% due to a loss to tubing and dilution. Furthermore, the use of dextrose‐based dialysate may require additional insulin to mitigate systemic impact of dextrose absorption on BG. Overall, a gap exists in the primary literature regarding recommendations for prophylactically adjusting insulin therapy when initiating HD or PD, or when switching between the two. More research is needed to clarify ideal alterations in insulin dosing, administration techniques, and product selections for PWD and ESKD undergoing dialysis.
- 9 January 2022
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 42 (2) , 177-187
Systematic literature review of insulin dose adjustments when initiating hemodialysis or peritoneal dialysis
Chronically uncontrolled hyperglycemia is the leading cause of end stage kidney disease (ESKD) necessitating dialysis. During times of transition to hemodialysis (HD) or peritoneal dialysis (PD), considerations must be given to insulin dosing adjustments for persons with diabetes (PWD) in efforts to maintain glycemic control. However, the literature is sparse with few clear and direct practical clinical recommendations for therapeutic insulin dosing adjustments in PWD and ESKD. The objective of this systematic review was to identify and report the evidence and gaps in the literature for adjustments in therapeutic insulin recommendations when initiating HD or PD in patients with ESKD and diabetes mellitus. A literature search using PubMed, CENTRAL, MEDLINE, CINAHL, Google Scholar, and ClinicalTrials.gov revealed 242 results. After removing duplicates and articles not reaching pre‐specified criteria, 29 relevant articles remained for further analysis. Following the exclusion of 18 articles after full‐text review due to lack of relevance or inappropriate publication type, 11 articles remained and were included in the review. The most common recommendation regarding HD was to reduce the basal insulin dose up to 25% on HD days to prevent hypoglycemia, although a lack of consensus exists on the percent reduction. Little information was found relating to insulin management with continuous ambulatory PD or automated PD. During PD, insulin may be administered subcutaneously, IP, or with the dialysis fluid. Administration of insulin with dialysate may necessitate a dose increase of up to 30% due to a loss to tubing and dilution. Furthermore, the use of dextrose‐based dialysate may require additional insulin to mitigate systemic impact of dextrose absorption on BG. Overall, a gap exists in the primary literature regarding recommendations for prophylactically adjusting insulin therapy when initiating HD or PD, or when switching between the two. More research is needed to clarify ideal alterations in insulin dosing, administration techniques, and product selections for PWD and ESKD undergoing dialysis.
- 7 March 2021
- Published by Wiley in Public Health Nursing
- Vol. 38 (4) , 579-587
Changes in attitudes toward diabetes in nursing students at diabetes camp
Aim: The research purpose was to determine whether exposure to residential diabetes camps affects attitudes toward diabetes care and management in nursing students.Background: Summer camp for children with type 1 diabetes mellitus (T1D) provides a unique and engaging clinical environment for nursing students to learn about evolving diabetes care and to help children develop diabetes management skills.Methods: This prospective, pretest/posttest study assessed student nurses' attitudes about diabetes, who attended one of four residential summer camps in the United States, using the Diabetes Attitude Survey 3 (DAS3). The survey was administered before and after clinical experience designed to fulfill experiential curricula requirements from various nursing programs.Results: After attending diabetes camp, nursing students (N = 73) had a positive change in their attitudes regarding the need for special training and the psychosocial impact of diabetes.Discussion: The diabetes camp clinical experience impacted nursing students' attitudes. Diabetes camps are a unique clinical setting that uses learned clinical knowledge and judgment to promote health and prevent disease and disability, supporting the integration of primary care and public health nursing.
- 7 March 2021
- Published by Wiley in Public Health Nursing
- Vol. 38 (4) , 579-587
Changes in attitudes toward diabetes in nursing students at diabetes camp
Aim: The research purpose was to determine whether exposure to residential diabetes camps affects attitudes toward diabetes care and management in nursing students.Background: Summer camp for children with type 1 diabetes mellitus (T1D) provides a unique and engaging clinical environment for nursing students to learn about evolving diabetes care and to help children develop diabetes management skills.Methods: This prospective, pretest/posttest study assessed student nurses' attitudes about diabetes, who attended one of four residential summer camps in the United States, using the Diabetes Attitude Survey 3 (DAS3). The survey was administered before and after clinical experience designed to fulfill experiential curricula requirements from various nursing programs.Results: After attending diabetes camp, nursing students (N = 73) had a positive change in their attitudes regarding the need for special training and the psychosocial impact of diabetes.Discussion: The diabetes camp clinical experience impacted nursing students' attitudes. Diabetes camps are a unique clinical setting that uses learned clinical knowledge and judgment to promote health and prevent disease and disability, supporting the integration of primary care and public health nursing.